Phenotypes associated with this allele
Igf1tm1Dlr/Igf1tm1Dlr Igfalstm1Yrb/Igfalstm1Yrb Tg(Alb1-cre)1Dlr/? mice exhibit reduced growth plate height
growth/size/body
|
|
• 30% reduction in total length by 2-3 weeks of age
|
skeleton
|
|
• reduced cortical bone thickness
• reduced trabecular bone volume and trabecular bone density
|
|
|
• 20% shorter at 21 days of age and 12% shorter at 6 weeks of age
|
|
|
• tibial growth plate height reduced by 20%
• germinal zone height increased in the tibia
|
limbs/digits/tail
|
|
• reduced cortical bone thickness
• reduced trabecular bone volume and trabecular bone density
|
|
|
• 20% shorter at 21 days of age and 12% shorter at 6 weeks of age
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Igf1tm1Dlr mutation
(2 available);
any
Igf1 mutation
(27 available)
Tg(Mx1-cre)1Cgn mutation
(7 available)
|
|
|
homeostasis/metabolism
growth/size/body
|
N |
• after induction with IFN at 24-28 days of age, mice exhibit normal postnatal body growth up to 53 days of age relative to control mice
(J:55718)
• after induction with PiPc at 4 weeks of age, mice exhibit no significant differences in body weight relative to control mice, as shown at 7 and 24 months of age
(J:121798)
|
renal/urinary system
|
N |
• after induction with PiPc, 6-mo-old mice exhibit no significant differences in serum and urine creatinine levels, GFR, creatinine clearance, or 24-hr urine volume relative to control mice
• no glomerulosclerosis, vascular defects, mesangial sclerosis, or cortical fibrosis is observed at 24 months of age
|
|
|
• after induction with PiPc, 6-mo-old mice exhibit increased 24-hr potassium excretion relative to control mice
|
|
|
• after induction with PiPc, 6-mo-old mice exhibit increased 24-hr sodium excretion relative to control mice
|
|
|
• after induction with PiPc, absolute and relative kidney weight is reduced in 7- and 24-month-old mice relative to control mice
|
cardiovascular system
|
|
• after induction with PiPc, 7-mo-old mice exhibit increased systolic blood pressure relative to control mice
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Igf1tm1Dlr mutation
(2 available);
any
Igf1 mutation
(27 available)
Tg(EIIa-cre)C5379Lmgd mutation
(4 available)
|
|
|
mortality/aging
|
|
• some perinatal mortality but many survive
|
growth/size/body
|
|
• 72% of control weight at 3 weeks of age, 68% at 6 weeks
|
|
|
• fetus at E19 or E20 weighs only 69% as much as comparable controls
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Igf1tm1Dlr mutation
(2 available);
any
Igf1 mutation
(27 available)
Tg(Alb1-cre)1Dlr mutation
(3 available)
|
|
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Igf1tm1Dlr mutation
(2 available);
any
Igf1 mutation
(27 available)
Tg(Alb1-cre)1Dlr mutation
(3 available)
|
|
|
homeostasis/metabolism
neoplasm
|
|
• male double mutant (LID, chronic liver-specific IGF-1 deficiency) mice on a high calorie diet for 10-14 weeks and injected with subcutaneous MC-39 murine colorectal carcinoma cell do not show the obesity-associated increase in local tumor growth compared to lean controls
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Igf1tm1Dlr mutation
(2 available);
any
Igf1 mutation
(27 available)
Tg(Serpina1e-cre/ERT)1Sykr mutation
(0 available)
|
|
|
homeostasis/metabolism
neoplasm
|
N |
• tamoxifen treatment of lean or obese mice before or after injection of MC-38 colon carcinoma cells does not alter the obesity-associated increase in tumor growth in contrast to what is observed in LID (chronic liver-specific IGF-1 deficiency) mice
|
Analysis Tools